Fierce Pharma

Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance

With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. | With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug ...
The National Law Review

Lung Cancer Antibody Drug Conjugates Market Size FDA Approved Lung Cancer ADC Clinical Trials Future Opportunity Insight

Global Lung Cancer Antibody Drug Conjugates Market Witnessing Exponential Growth Says Kuick Research Delhi, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Global Lung Cancer Antibody Drug Conjugates Market ...
Nasdaq

MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer

Merck (MRK) and its Japanese partner Daiichi Sankyo announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to their investigational pipeline candidate, raludotatug deruxtecan ...
Morningstar

BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC

BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma This Becotatug Vedotin injection approval is BioDlink's ...

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Company expands its ADC pipeline and patent estate for novel, differentiated ADCsNew pipeline candidate AKTX-102 leverages ...
Morningstar

Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint

CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded ...